Kaplan-Meier curves with 6-week landmark analysis for (A) progression-free survival (B) and overall survival in patients with or without irAEs. irAEs indicates immune-related adverse events; NR, not reached.
eMethods. Data collection and statistical analysis
eTable 1. Characteristics of the 134 study patients
eTable 2. Patient characteristics according to immune-related adverse events (irAEs) at the 6-week landmark for progression-free survival
eFigure 1. Kaplan-Meier curves with 4-week landmark analysis for progression-free survival (A) and overall survival (B) according to the absence or presence of any immune-related adverse event (irAE)
eFigure 2. Kaplan-Meier curves with 8-week landmark analysis for progression-free survival (A) and overall survival (B) according to the absence or presence of any immune-related adverse event (irAE)
eFigure 3. Kaplan-Meier curves with 6-week landmark analysis for progression-free survival according to the absence or presence of a skin (A) or endocrine (B) immune-related adverse event (irAE)
eFigure 4. Kaplan-Meier curves with 6-week landmark analysis for overall survival according to the absence or presence of a skin (A) or endocrine (B) immune-related adverse event (irAE)
Customize your JAMA Network experience by selecting one or more topics from the list below.
Haratani K, Hayashi H, Chiba Y, et al. Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non–Small-Cell Lung Cancer. JAMA Oncol. 2018;4(3):374–378. doi:10.1001/jamaoncol.2017.2925
Are immune-related adverse events associated with outcome of nivolumab treatment in patients with non–small-cell lung cancer (NSCLC)?
In this multi-institutional medical record review including 134 patients with advanced or recurrent NSCLC treated with nivolumab monotherapy, landmark and multivariable analyses showed that immune-related adverse events were significantly associated with a better treatment outcome.
Early recognition and proper management of immune-related adverse events are important to maximize the therapeutic benefit of immune-checkpoint inhibitors in patients with NSCLC.
Immune-related adverse events (irAEs) have been associated with the efficacy of PD-1 (programmed cell death protein 1) inhibitors in patients with melanoma, but whether such an association exists for non–small-cell lung cancer (NSCLC) has remained unknown.
To evaluate the relation of irAEs to nivolumab efficacy in NSCLC.
Design, Setting, and Participants
In this study based on landmark and multivariable analyses, a total of 134 patients with advanced or recurrent NSCLC who were treated with nivolumab in the second-line setting or later between December 2015 and August 2016 were identified from a review of medical records from multiple institutions, including a university hospital and community hospitals. Data were updated as of December 31, 2016.
The absence or presence of any irAE before the landmark date.
Main Outcomes and Measures
Kaplan-Meier curves of progression-free survival (PFS) according to the development of irAEs in 6-week landmark analysis were evaluated with the log-rank test as a preplanned primary objective. Overall survival (OS) was similarly evaluated. Multivariable analysis of both PFS and OS was performed with Cox proportional hazard regression models.
In a cohort of 134 patients (median [range] age, 68 [33-85] years; 90 men [67%], 44 women [33%]), irAEs were observed in 69 of the 134 study patients (51%), including 12 patients (9%) with such events of grade 3 or 4, and 24 patients (18%) requiring systemic corticosteroid therapy. In 6-week landmark analysis, median PFS was 9.2 months (95% CI, 4.4 to not reached [NR]) and 4.8 months (95% CI, 3.0 to 7.5) (P = .04) whereas median OS was NR (95% CI, 12.3 to NR) and 11.1 months (95% CI, 9.6 to NR) (P = .01) for patients with or without irAEs, respectively. Multivariable analysis also revealed that irAEs were positively associated with survival outcome, with hazard ratios of 0.525 (95% CI, 0.287 to 0.937; P = .03) for PFS and 0.282 (95% CI, 0.101 to 0.667; P = .003) for OS.
Conclusions and Relevance
Development of irAEs was associated with survival outcome of nivolumab treatment in patients with advanced or recurrent NSCLC. Further studies are needed to confirm our findings.
The development of immunotherapy has improved treatment outcome for various types of cancer including non–small-cell lung cancer (NSCLC). Nivolumab and pembrolizumab, monoclonal antibodies that target PD-1 (programmed cell death protein 1), have been approved for the treatment of metastatic NSCLC on the basis of recent clinical trials demonstrating that these agents prolong survival compared with cytotoxic chemotherapy.1-4 On the other hand, treatment with such immune-checkpoint inhibitors is accompanied by immune-related adverse events (irAEs).5,6 The development of irAEs has been found to be associated with survival benefit in melanoma,7-11 suggesting that an early onset of irAEs might be predictive of a better outcome of treatment with immune-checkpoint inhibitors and that the proper management of such events might be required to maximize the therapeutic effect of these drugs. The relation between irAEs and outcome of such treatment for patients with NSCLC has remained unknown, however.
We performed a multi-institutional retrospective study to investigate the irAE profile and its association with clinical activity for nivolumab in NSCLC with the use of landmark and multivariable analyses.
We reviewed the medical records of all patients with advanced or recurrent NSCLC who were treated with nivolumab at 4 participating institutions. The end of the follow-up period was December 31, 2016. The study was performed according to protocols approved by the institutional review board of each participating hospital.
The difference in progression-free survival (PFS) curves estimated with the Kaplan-Meier method according to the absence or presence of any irAE in 6-week landmark analysis was evaluated with the log-rank test as a preplanned primary objective. Univariable and multivariable Cox proportional hazard regression models were adopted to determine hazard ratios. Multivariable analysis was performed with adjustment for age, sex, the number of prior treatment lines, smoking status, mutational status, and brain metastases. Taking into account the lead-time bias due to the time-dependent nature of irAEs, we performed 6-week landmark analysis including only patients manifesting disease control or those who were alive at 42 days after initiation of nivolumab therapy for PFS (n = 105) or overall survival (OS) (n = 130), respectively. Both analyses were carried out on the basis of this landmark assessment of irAEs that developed within the first 6 weeks. In addition, 4-week and 8-week landmark analyses were performed as complementary evaluations. Any irAE occurring after the landmark date was not counted in the landmark-based analyses. All P values were based on a 2-sided hypothesis, and those less than .05 were considered statistically significant. Detailed methods for data collection and statistical analysis are provided in eMethods in the Supplement.
A total of 134 NSCLC patients treated with nivolumab were included in the study (eTable 1 in the Supplement). For 6-week landmark analysis, 29 patients were excluded because of disease progression or death before day 43 of nivolumab treatment for analysis of PFS (eTable 2 in the Supplement) and 4 patients were excluded because of death before this time for analysis of OS. The irAE profile is shown in Table 1.
Six-week landmark analysis showed that the overall response rate was significantly higher in patients with irAEs than in those without them (23 of 44 patients [52.3%] vs 17 of 61 patients [27.9%]; P = .02) and that the development of irAEs was significantly associated with increased PFS (P = .04) and OS (P = .01) (Figure). Similar results were obtained for 4-week and 8-week landmark analyses (eFigures 1 and 2 in the Supplement). Six-week landmark analyses for irAE subgroups revealed skin irAEs were significantly associated with increased PFS (eFigures 3 and 4 in the Supplement).
Multivariable analysis revealed that any irAE, skin irAEs, and endocrine irAEs were significantly associated with increased PFS at the 6-week landmark (Table 2). Any irAE and skin irAEs were significantly associated with increased OS, whereas endocrine irAEs were not, possibly because of the small number of patients with endocrine irAEs at this landmark and the insufficient follow-up time for OS.
Our results have revealed that irAEs were associated with nivolumab efficacy in patients with NSCLC. Our landmark analyses—including the principal 6-week analysis, complemented by additional 4-week and 8-week analyses—minimized lead-time bias potentially associated with time-dependent factors such as irAEs. The association of irAEs with nivolumab efficacy was further supported by multivariable analysis. Furthermore, given that our data are derived from multiple institutions including community hospitals, our findings should be applicable to a general NSCLC population.
Some previous studies did not detect a significant association of irAEs with survival outcome in patients with melanoma, especially with regard to PFS because of the exclusion of many patients who experienced disease progression before the landmark date.10,12 Nevertheless, our 6-week landmark analysis revealed a significant difference in both PFS and OS between patients with NSCLC with or without irAEs, suggestive of a robust association between such events and survival. Setting the landmark at 6 weeks for a study of patients with NSCLC treated with a PD-1 inhibitor seems reasonable because such individuals tend to experience disease progression earlier or at a higher rate compared with patients with melanoma. Of note, our early landmark analyses before routine response evaluation also suggest that an early onset of irAEs might be predictive of response or durable clinical benefit in patients with NSCLC treated with PD-1 inhibitors.
The mechanisms underlying the association of irAEs with outcome of treatment with PD-1 inhibitors are unknown. Previous studies showing an association of vitiligo with outcome of immunotherapy in patients with melanoma have suggested that antigens shared between melanoma cells and normal melanocytes might contribute to this association.7,9,11 Whether lung cancer cells share antigens with tissues affected by irAEs in patients with NSCLC remains to be determined. A recent study13 suggested that OS is prolonged in NSCLC patients receiving immunotherapy who develop immune-related thyroiditis compared with those without thyroiditis. Another study suggested an association between skin irAEs and improved OS in patients with NSCLC treated with nivolumab.14 Our multivariable analysis at the 6-week landmark showing increased PFS or OS according to the presence of endocrine or skin irAEs are consistent with these previous findings.
There are some limitations to our study. First, the study was retrospective in nature, so information bias cannot be excluded. Second, our multivariable analysis could not include all potential confounding factors because of the limited number of covariates available for the sample size. Third, the follow-up time was not long enough to allow us to fully address long-term survival outcome. Fourth, the various types of irAE, with the exception of those affecting skin, were not common, thus limiting our evaluation of which type of irAE most strongly contributes to the association with treatment outcome. The association between non-skin irAEs and nivolumab efficacy thus remains inconclusive and warrants further study with larger cohorts.
Our findings indicate that irAEs are associated with nivolumab efficacy in patients with NSCLC. As far as we are aware, our study is the first to reveal an association of irAEs with the efficacy of PD-1 inhibitors in NSCLC with landmark and multivariable analyses. Further studies with larger numbers of patients and longer follow-up times are needed to validate our findings.
Corresponding Author: Hidetoshi Hayashi, MD, PhD, Department of Medical Oncology, Kindai University Faculty of Medicine, 377-2 Ohno-Higashi, Osaka-Sayama, Osaka 589-8511, Japan (email@example.com).
Accepted for Publication: June 28, 2017.
Published Online: September 21, 2017. doi:10.1001/jamaoncol.2017.2925
Author Contributions: Drs Haratani and Hayashi had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
Study concept and design: Haratani, Hayashi, Nakagawa.
Acquisition, analysis, or interpretation of data: Haratani, Hayashi, Chiba, Kudo, Yonesaka, Kato, Kaneda, Hasegawa, Tanaka, Takeda, Nakagawa.
Drafting of the manuscript: Haratani, Hayashi.
Critical revision of the manuscript for important intellectual content: Haratani, Hayashi, Chiba, Kudo, Yonesaka, Kato, Kaneda, Hasegawa, Tanaka, Takeda, Nakagawa.
Statistical analysis: Haratani, Hayashi, Chiba.
Administrative, technical, or material support: Yonesaka, Kato, Kaneda, Hasegawa, Tanaka, Takeda.
Study supervision: Hayashi, Nakagawa.
Conflict of Interest Disclosures: Dr Haratani has received honoraria from Ono Pharmaceutical Co Ltd, as well as lecture fees from Pfizer Japan Inc and Bristol-Myers Squibb Co Ltd. Dr Hayashi has received honoraria from AstraZeneca KK, Boehringer Ingelheim Japan Inc, Bristol-Myers Squibb Co Ltd, Eli Lilly Japan KK, Ono Pharmaceutical Co Ltd, and Taiho Pharmaceutical Co Ltd; lecture fees from Chugai Pharmaceutical Co Ltd, Kyowa Hakko Kirin Co Ltd, MSD KK, and Pfizer Japan Inc; and research funding from Ono Pharmaceutical Co Ltd. Dr Kaneda has received lecture fees from AstraZeneca KK, Boehringer Ingelheim Japan Inc, Bristol-Myers Squibb Co Ltd, Chugai Pharmaceutical Co Ltd, Eli Lilly Japan KK, and Pfizer Japan Inc. Dr Tanaka has received lecture fees from AstraZeneca KK and Merck Serono Co Ltd. Dr Nakagawa has received honoraria from Astellas Pharma Inc, AstraZeneca KK, AYUMI Pharmaceutical Corp, Boehringer Ingelheim Japan Inc, Bristol-Myers Squibb Co Ltd, Chugai Pharmaceutical Co Ltd, Daiichi Sankyo Co Ltd, Eli Lilly Japan KK, Kissei Pharmaceutical Co Ltd, Kyowa Hakko Kirin Co Ltd, MSD KK, Novartis Pharma KK, Ono Pharmaceutical Co Ltd, Pfizer Japan Inc, Showa Yakuhin Kako Co Ltd, Sym Bio Pharmaceuticals Ltd, and Taiho Pharmaceutical Co Ltd; research funding from AbbVie Inc, Astellas Pharma Inc, AstraZeneca KK, Boehringer Ingelheim Japan Inc, Bristol-Myers Squibb Co Ltd, Daiichi Sankyo Co Ltd, Eisai Co Ltd, Eli Lilly Japan KK, GlaxoSmithKline KK, Kyowa Hakko Kirin Co Ltd, Merck Serono Co Ltd, MSD KK, Novartis Pharma KK, Ono Pharmaceutical Co Ltd, Otsuka Pharmaceutical Co Ltd, Pfizer Japan Inc, Taiho Pharmaceutical Co Ltd, Takeda Pharmaceutical Co Ltd, and Yakult Honsha Co Ltd; and consulting or advisory fees from Astellas Pharma Inc, Eli Lilly Japan KK, and Ono Pharmaceutical Co Ltd. No other disclosures are reported.
Additional Contributions: We thank all the patients and medical staff at the participating institutions who contributed to this study.